OPK vs. PCRX, TARO, AVIR, ADCT, HRMY, FOLD, CLDX, GERN, MYGN, and NVAX
Should you be buying OPKO Health stock or one of its competitors? The main competitors of OPKO Health include Pacira BioSciences (PCRX), Taro Pharmaceutical Industries (TARO), Atea Pharmaceuticals (AVIR), ADC Therapeutics (ADCT), Harmony Biosciences (HRMY), Amicus Therapeutics (FOLD), Celldex Therapeutics (CLDX), Geron (GERN), Myriad Genetics (MYGN), and Novavax (NVAX). These companies are all part of the "medical" sector.
Pacira BioSciences (NASDAQ:PCRX) and OPKO Health (NASDAQ:OPK) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, earnings, community ranking, analyst recommendations, valuation, institutional ownership, dividends, risk and media sentiment.
Pacira BioSciences currently has a consensus price target of $43.60, suggesting a potential upside of 117.67%. OPKO Health has a consensus price target of $2.50, suggesting a potential upside of 68.92%. Given OPKO Health's higher probable upside, analysts clearly believe Pacira BioSciences is more favorable than OPKO Health.
Pacira BioSciences received 315 more outperform votes than OPKO Health when rated by MarketBeat users. Likewise, 71.84% of users gave Pacira BioSciences an outperform vote while only 65.57% of users gave OPKO Health an outperform vote.
Pacira BioSciences has higher earnings, but lower revenue than OPKO Health. OPKO Health is trading at a lower price-to-earnings ratio than Pacira BioSciences, indicating that it is currently the more affordable of the two stocks.
Pacira BioSciences has a beta of 0.88, indicating that its share price is 12% less volatile than the S&P 500. Comparatively, OPKO Health has a beta of 1.65, indicating that its share price is 65% more volatile than the S&P 500.
Pacira BioSciences has a net margin of 10.34% compared to Pacira BioSciences' net margin of -31.44%. OPKO Health's return on equity of 12.98% beat Pacira BioSciences' return on equity.
99.7% of Pacira BioSciences shares are owned by institutional investors. Comparatively, 64.6% of OPKO Health shares are owned by institutional investors. 6.4% of Pacira BioSciences shares are owned by company insiders. Comparatively, 47.3% of OPKO Health shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
In the previous week, OPKO Health had 9 more articles in the media than Pacira BioSciences. MarketBeat recorded 15 mentions for OPKO Health and 6 mentions for Pacira BioSciences. OPKO Health's average media sentiment score of 0.56 beat Pacira BioSciences' score of 0.49 indicating that Pacira BioSciences is being referred to more favorably in the media.
Summary
Pacira BioSciences beats OPKO Health on 13 of the 18 factors compared between the two stocks.
Get OPKO Health News Delivered to You Automatically
Sign up to receive the latest news and ratings for OPK and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding OPK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
OPKO Health Competitors List
Related Companies and Tools
